Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy

Mavacamten is a first-in-class, targeted, cardiac-specific myosin inhibitor approved by the US Food and Drug Administration for the treatment of adults with symptomatic New York Heart Association Classes II and III obstructive hypertrophic cardiomyopathy (oHCM). Mavacamten was developed to target th...

Descripción completa

Detalles Bibliográficos
Autores principales: Braunwald, Eugene, Saberi, Sara, Abraham, Theodore P, Elliott, Perry M, Olivotto, Iacopo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
State of the Art Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10659958/
https://www.ncbi.nlm.nih.gov/pubmed/37804245
http://dx.doi.org/10.1093/eurheartj/ehad637

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10659958/
https://www.ncbi.nlm.nih.gov/pubmed/37804245
http://dx.doi.org/10.1093/eurheartj/ehad637

Ejemplares similares